News | January 20, 2012

Study Examines Ultrasound Accelerated Thrombolysis in Acute PE

The Ekos drug delivery catheters deliver the lytic drug, while the non-cavitational ultrasound energy gently perfuses the drug deep into the clot, limiting the amount that escapes downstream.

January 20, 2012 - Robert J. Kennedy, M.D., interventional radiologist at Holmes Regional Medical Center in Melbourne, Fla., this week presented data on thrombus resolution and hemodynamic recovery using ultrasound accelerated thrombolysis in acute pulmonary embolism (PE) at the International Symposium on Endovascular Therapy (ISET).

“New treatment guidelines increasingly favor catheter-directed techniques for the treatment of acute PE targeting high-risk patients whose hemodynamic status is unstable, as well as intermediate-risk patients whose conditions may be stable but exhibit poor outcomes if large thrombus burdens remain,” Kennedy said. His study evaluates the safety and effectiveness of ultrasound accelerated thrombolysis when prompt treatment is warranted to rapidly resolve the thrombus and improve cardiopulmonary function.

“We retrospectively reviewed our experience in treating consecutive acute PE patients between 2009 and 2011,” Kennedy said. “Upon diagnosis of PE by pulmonary CTA or V/Q scan, all patients received anticoagulant therapy and treatment using the Ekosonic Endovascular system which was placed into the thrombus to facilitate ultrasound-accelerated thrombolytic infusion at 0.5 or 1 mg/hour/catheter.”

Kennedy reported that patient outcomes, including clinical improvement, pulmonary artery pressure, thrombus removal (Miller score) and complications, were documented to evaluate treatment success following overnight thrombolytic infusion. 

He reported that treatment of 40 patients (25 men, 15 women; aged 60±17; 35 bilateral PE) resulted in complete thrombus clearance (90 percent) in 25 and near-complete (50-90 percent) clearance in the remaining 15 patients following infusion of 34±12 mg tPA over 20.3±7.2 hours.  Mean pulmonary artery pressure decreased significantly from pre- to post-treatment (47±16 to 38±13, p<.001), as did the Miller score (25±3 to 17±5, p<.001). Clinical improvement of symptoms was observed in all 40 patients post-treatment, with no major hemorrhagic complications. All patients survived to hospital discharge with a median length of one-day ICU stay and nine days hospital stay.  

The current study demonstrates safety and effectiveness of ultrasound accelerated thrombolysis in treating a population of patients with severe thrombus burden and increased risk for poor outcomes when untreated or undertreated. Treatment success was predictable, with angiographic evidence of thrombus clearance corroborated by significant reduction of pulmonary artery pressure and Miller score using a low dose thrombolytic infusion protocol.

For more information:

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init